Program Detail

Modality
Program #
Program
indication
Presentation

Source
COVID-19 vaccine

Last program update Sep 18, 2020

Source
Cytomegalovirus (CMV) vaccine

Last program update Sep 18, 2020

Source
Human metapneumovirus and parainfluenza virus 3 (hMPV/PIV3) vaccine

Last program update Sep 18, 2020

Source
Respiratory syncytial virus (RSV) vaccine

Last program update Aug 05, 2020

Source
Zika vaccine

Last program update Aug 05, 2020

Source
Pediatric respiratory syncytial virus (RSV) vaccine \n\iFuture respiratory combo/i

Last program update Sep 18, 2020

Source
Epstein-Barr virus (EBV) vaccine

Last program update Aug 05, 2020

Source
Influenza H7N9 vaccine

Last program update Aug 05, 2020

Source
Antibody against Chikungunya virus

Last program update Sep 18, 2020

Source
Relaxin \n\iHeart failure/i

Last program update Aug 05, 2020

Source
PD-L1 \n\i Autoimmune hepatitis

Last program update Aug 05, 2020

Source
IL-2 \n\i Autoimmune disorders

Last program update Aug 05, 2020

Source
Personalized Cancer Vaccine (PCV) \n\iSolid tumors/i

Last program update Aug 05, 2020

Source
KRAS vaccine \n\iCRC, NSCLC, pancreatic cancer/i

Last program update Aug 05, 2020

Source
OX40L \n\iSolid tumors/lymphoma/i\n\iAdvanced ovarian carcinoma/i

Last program update Sep 18, 2020

Source
OX40L/IL-23/IL-36y \n\iSolid tumors/lymphoma/i

Last program update Sep 18, 2020

Source
IL-12 \n\iSolid tumors/i

Last program update Aug 05, 2020

Source
VEGF-A \n\iMyocardial ischemia/i

Last program update Aug 05, 2020

Source
PCCA/PCCB\n\iPropionic acidemia (PA)/i

Last program update Sep 18, 2020

Source
MUT \n\iMethylmalonic acidemia (MMA)/i

Last program update Sep 18, 2020

Source
PAH \n\iPhenylketonuria (PKU)/i

Last program update Aug 05, 2020

Source
G6Pase \n\iGlycogen storage disorder type 1a (GSD1a)/i

Last program update Aug 05, 2020